| イスラエル | トルコ | オーストリア | |
| 陽子線治療 | から $48,000 | から $70,000 | から $80,000 |
| 腹腔内温熱化学療法 | から $61,200 | から $22,500 | から $40,000 |
| 胃癌手術 | から $28,500 | から $22,320 | から $30,000 |
| 胃切除術 | から $22,500 | から $16,470 | から $22,000 |
| 胃切除術 | から $24,500 | から $18,300 | から $25,000 |
ペレス・シャロン医師は、ソウラスキー医療センターにおける消化器腫瘍部門を率いており、ロンドンのロイヤル・マーズデン癌センターにてデイヴィッド・カニンガム教授のもとで研鑽を積みました。
メリムスキー教授は、スーラスキー医療センターの軟部組織・骨腫瘍科を率い、複雑な肉腫症例を専門としています。
この医師は、消化管腫瘍の治療において30年以上の経験を持つ、著名な消化器専門医です。GIがんの予防、早期診断、および治療を専門としており、Sourasky Medical CenterのCancer Prevention Centerを率いています。
ヘブライ大学で一般医学の学位を取得し、テルアビブ大学で消化器学の専門を修了したこの医師は、NewYork-Presbyterian Centerで研究を行いました。この医師は300以上の論文を発表しており、American Association for Cancer ResearchやEuropean Society of Digestive Oncologyを含む、いくつかの著名な組織のメンバーです。
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Stomach cancer treatment in Israel involves multidisciplinary protocols combining D2 lymphadenectomy, advanced chemotherapy, and targeted immunotherapy. JCI-accredited centers like Sourasky and Sheba specialize in Da Vinci robotic resections. This technology improves surgical precision and accelerates recovery times for gastric cancer patients.
Bookimed Expert Insight: Israeli oncology centers demonstrate high efficiency by integrating rapid molecular diagnostics with surgical planning. Data shows Sourasky Medical Center maintains a 90% oncology success rate while treating over 400,000 patients annually. For patients seeking robotic surgery, Dr. Pelles Sharon and Professor Ido Nachmany are noted specialists who utilize these minimally invasive techniques to reduce hospital stays.
Patient Consensus: Patients note it's important to arrange private care to avoid long public waitlists and emphasize the value of detailed treatment plans provided by specialists. Many feel more confident after receiving clear explanations about robotic options and supportive care for post-surgery recovery.
Top hospitals for stomach cancer in Israel include Sheba Medical Center, Sourasky Medical Center (Ichilov), and Hadassah Medical Center. These JCI-accredited facilities offer advanced gastric resection, HIPEC, and Da Vinci robotic surgery. They maintain high oncology success rates through multidisciplinary tumor boards and precision medicine protocols.
Bookimed Expert Insight: Patient volume data often reveals hidden expertise in specific surgical techniques. While Sourasky handles over 400,000 patients yearly, specialists like Dr. Joseph Klauzner bring over 45 years of experience to complex gastrointestinal surgeries. Choosing a high-volume center with senior surgeons who perform 1,000+ procedures ensures access to refined recovery protocols and lower complication risks.
Patient Consensus: Patients note the value of getting a treatment plan quickly through remote consultations with specialists like Dr. Pelles Sharon or Professor Ayala Hubert. Personal coordination is often the deciding factor for those seeking fast access to advanced robotic surgery or clinical trials.
Stomach cancer surgery in Israel typically requires a 5 to 14 day hospital stay. Minimally invasive robotic or laparoscopic procedures often reduce this to 3 days. Full physical recovery generally takes 8 weeks. Long-term dietary adjustments commonly continue for up to 12 months.
Bookimed Expert Insight: Israeli oncology centers like Sourasky (Ichilov) maintain a 90% success rate by prioritizing rapid mobilization. Data shows that even for complex gastric resections, surgeons like Dr. Joseph Klauzner leverage over 45 years of experience to minimize inpatient time. Many high-volume centers in Tel Aviv combine surgery with immediate post-operative monitoring efficiently, often allowing international patients to safely fly home within 15 days of the procedure.
Patient Consensus: Patients often note that while initial discharges happen quickly, the real challenge is managing small, frequent meals at home. Many express gratitude for detailed treatment plans that clarify the transition from hospital care to independent recovery.
Targeted and biological therapies are routinely used for gastric cancer in Israel as part of the National Health Basket. Treatment selection depends on molecular profiling to match specific drugs to the tumor. Common options include Trastuzumab for HER2-positive cases and immunotherapy like Pembrolizumab for specific genetic markers.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center prioritize academic research integration for complex cases. Dr. Pelles Sharon at Sourasky specifically focuses on clinical trials for digestive system cancers. This means patients may access experimental biological therapies before they become global standards. Our data shows a 90% oncology success rate at this JCI-accredited facility in Tel Aviv.
Patient Consensus: Patients emphasize the need to explicitly request HER2 and MSI/MMR testing during the initial consultation. Many note that while major centers in Tel Aviv offer advanced options, availability can vary in smaller regional hospitals.